Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 54 for:    Recruiting, Not yet recruiting, Available Studies | NOT (Use Disorders OR Marijuana Use OR Dependence OR Abuse OR Drug Use) | cannabinoids

Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03944954
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : May 10, 2019
Sponsor:
Information provided by (Responsible Party):
Michael J. Wesley, PhD, University of Kentucky

Brief Summary:
Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. The proposed research will combine clinical pharmacology, non-invasive brain stimulation, and neuroimaging techniques to establish the brain mechanisms of cannabinoid-impaired decision-making processes in emerging adults with CUD. Results from this project will inform CUD prevention/treatment efforts in this high-risk group and address a growing public health concern.

Condition or disease Intervention/treatment Phase
Neurosciences Substance-Related Disorders Behavior Problem Drug: Marinol Device: Transcranial Magnetic Stimulation Early Phase 1

Detailed Description:

This mentored career development award (K01) will enable Dr. Michael J. Wesley to achieve his long-term goal of becoming an independent investigator with a clinical research program examining cannabis use disorder (CUD) in emerging adults, which is a current NIDA funding priority. Dr. Wesley is a new Assistant Professor at the University of Kentucky (UK) College of Medicine. The activities proposed in this award build on Dr. Wesley's background in neuroimaging and drug abuse research and will allow him to accomplish these specific short-term objectives: Become an expert in (1) clinical pharmacology and (2) non-invasive brain stimulation research, and enhance/develop his (3) knowledge of the responsible conduct of research, (4) skills for scientific communication and grant writing, and (5) ability to manage an independent research program. UK has numerous faculty and projects focused on drug abuse research and is an ideal environment for Dr. Wesley to successfully complete this award. Dr. Wesley has assembled a stellar mentoring team consisting of Dr. Josh Lile (Mentor), who runs a successful NIH-funded clinical pharmacology research program at UK and Drs. Mark George (Co-Mentor) and Colleen A. Hanlon of the Brain Stimulation Laboratory at the Medical University of South Carolina, Together they will guide and oversee Dr. Wesley's training in clinical pharmacology, brain stimulation, and scientific communication and grant writing. Dr. Wesley has proposed to engage in a series of formal classes, lab exchanges, and research seminars/meetings that will assist him in accomplishing the objectives of this award.

The proposed research project is novel, innovative, and rigorous. It will combine the acute administration of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, with brain stimulation and neuroimaging to examine the role of the dorsal lateral prefrontal cortex (DLPFC) and connected brain areas in drug-impaired decision-making processes. Specifically, transcranial magnetic stimulation (TMS) will be used to raise or lower DLPFC functionality following the administration THC in randomized, double-blind, placebo- and sham-controlled experiments.

Aim 1 will test the hypotheses that excitatory TMS (raising DLPFC functionality; Exp. 1) will attenuate, whereas inhibitory TMS (lowering DLPFC functionality; Exp.2) will enhance, the impairing effects of THC on study outcomes.

Aim 2 will use neuroimaging to test the hypothesis that individual differences in brain structure and function predict the specific and/or combined effects of THC and TMS on study outcomes. Results from this project will improve the investigator's understanding of the mechanisms involved in cannabis-impaired decision-making, which will inform CUD management and address a growing public health concern.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: All individuals will receive multiple doses of oral THC (0, 10 and 30mg). Additionally, group 1 will receive excitatory TMS and group 2 will receive inhibitory TMS (real and sham in each group).
Masking: Single (Investigator)
Masking Description: Functionality will be tested following combinations of THC and TMS will be tested in randomized, double-blind, placebo- and sham-controlled experiments.
Primary Purpose: Basic Science
Official Title: Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
Actual Study Start Date : July 15, 2017
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Dronabinol

Arm Intervention/treatment
Experimental: Excitatory TMS
Combinations of THC and excitatory TMS.
Drug: Marinol
Individuals will receive 0, 10, 30mg of Marinol.
Other Name: THC

Device: Transcranial Magnetic Stimulation
Individuals will receive excitatory or inhibitory TMS
Other Name: TMS

Experimental: Inhibitory TMS
Combinations of THC and inhibitory TMS.
Drug: Marinol
Individuals will receive 0, 10, 30mg of Marinol.
Other Name: THC

Device: Transcranial Magnetic Stimulation
Individuals will receive excitatory or inhibitory TMS
Other Name: TMS




Primary Outcome Measures :
  1. Learning Rate [ Time Frame: 4 Years ]
    In a Probabilistic Reinforcement Learning Choice (PRLC) task, two stimuli are presented and choosing either could result in a monetary reinforcer, but the reinforcement probabilities of the stimuli differ, and change throughout the task. Individuals attempt to optimize choices according to learned probabilities and track changing probabilities over time. PRLC performance allows mathematical modeling of trial-by-trial data under "real-world" uncertainty and yields computational parameters, such as the learning rate. Learning rates should favor recent changes in the experience of rewards so that individuals may have up-do-date representations of the world and reduced influence of irrelevant information while problem solving. We expect excitatory transcranial magnetic stimulation of the dorsal lateral prefrontal cortex, a brain area engaged by problem solving, to reduce the negative impact of increasing doses of THC on learning rates.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 25 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Habitual cannabis use problems
  • Body Mass Index ≤30

Exclusion Criteria:

  • Past or current serious physical or mental health
  • Sesame seed oil allergy
  • Irregular health issues identified by the Study Physician
  • Standard magnetic resonance imaging and transcranial magnetic stimulation exclusion criteria (e.g., metal implants, history of epilepsy, etc.)
  • Lack of affective form of birth control (females)
  • Pregnancy (females)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03944954


Contacts
Layout table for location contacts
Contact: Levi Bolin, PhD 859-323-0579 Levi.Bolin@uky.edu

Locations
Layout table for location information
United States, Kentucky
Neurobehavioral Systems Lab of the University of Kentucky College of Medicine Recruiting
Lexington, Kentucky, United States, 40507
Contact: Levi Bolin, PhD    859-562-1401    Levi.Bolin@uky.edu   
Sponsors and Collaborators
University of Kentucky
Investigators
Layout table for investigator information
Principal Investigator: Michael J Wesley, PhD University of Kentucky

Layout table for additonal information
Responsible Party: Michael J. Wesley, PhD, Assistant Professor, University of Kentucky
ClinicalTrials.gov Identifier: NCT03944954     History of Changes
Other Study ID Numbers: K01DA043652 ( U.S. NIH Grant/Contract )
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: May 10, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cannabinoid Receptor Agonists
Cannabinoid Receptor Modulators
Substance-Related Disorders
Problem Behavior
Chemically-Induced Disorders
Mental Disorders
Behavioral Symptoms
Dronabinol
Hallucinogens
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists